Novel tumour biomarker
SUBSTANCE: invention relates to biochemistry. Method includes determination of level of polypeptide with said sequence in plasma by means of antigen, where Thr90 of polypeptide is phosphorylated. Also diagnostic sets for detection of presence of tumour metastases are described, for screening for presence of tumour among high risk population, for determination of prognosis for patient, for determination of efficiency of surgery, radiotherapy or chemical therapy with respect to patient with tumour, and/or determination of the time when treatment must be stopped. Diagnostic sets include polypeptide with sequence, given in materials, where Thr90 of polypeptide is phosphorylated.
EFFECT: described are methods for detection of presence or metastases of tumour, screening for presence of tumour among high risk population, prognosis for patient with tumour, determination of efficiency of surgery, radiotherapy or chemical therapy.
27 cl, 20 dwg, 18 ex
SUBSTANCE: invention refers to medicine, namely to transfusion medicine, and is applicable in selecting blood plasma donors. That is ensured by sampling blood plasma to be analysed for antimicrobial peptides defensins. If the male defensin titre is from 180 to 545 ng/ml, and the female one is from 128 to 386 ng/ml, a donor is considered to be suitable for blood plasma drawing.
EFFECT: invention enables using the donor plasma in treating the patients suffering from infectious diseases and postoperative, injury and burn complications.
SUBSTANCE: invention relates to medicine, namely to pediatrics, and can be applied for predicting reduction of child's health level at the age of 12-16. For this purpose an hour after meal and 15 minutes before mouth fluid sampling oral cavity is washed with 0.9% sodium chloride solution. Analysis of child's mouth fluid with determination of ratio of immunoglobulin A concentration to immunoglobulin G concentration is performed. Analysis is carried out twice with difference in 14 days. In case of 1.4 fold and higher reduction of immunoglobulin A concentration to immunoglobulin G concentration ratio during second analysis child is allocated to group of risk of health level reduction.
EFFECT: application of claimed method makes it possible to carry out screening in the process of carrying out prophylactic medical examination to plan health-improving procedures in groups of dispensary observation.
SUBSTANCE: invention refers to medicine, namely to gynaecology, and concerns a method for the prediction of endometrial hyperplasia in the patients with hysteromyoma following uterine artery embolisation (UAE). Substance of the method: all the patients undergo a pre-UEA diagnostic and therapeutic uterine scrapping; 6 months after the UAE, an endometrial pipelle biopsy followed by a pathomorphological study of the biopsy material is conducted. If the study shows no pathology, the biopsy materials are analysed by means of an immune histochemical study using anti-Ki-67 monoclononal antibodies; a percentage of Ki-67 proliferation marker in the uterine gland epithelium (coefficient A) and in the endometrial stroma (coefficient B) is determined; a prognostic index D1 is calculated in initial(pre-UEA) non-atypical hyperplasia, and a prognostic index D2 - in initial (pre-UEA) endometrium in the late proliferation phase: D1=A*0.05-0.74 and D2=B*0.02-0.3. If D1 is 0 or more, recurrent endometrial hyperplasia is predicted, whereas D1 less than 0 enables stating a low risk of recurrent endometrial hyperplasia. If D2 is more than 0, a low risk of developing endometrial hyperplasia is stated, whereas D2 of 0 or less shows developing endometrial hyperplasia.
EFFECT: presented method enables the high-accuracy prediction of the post-UEA endometrial hyperplasia that makes it possible to prescribe the preventive hormone therapy in due time.
SUBSTANCE: claimed invention relates to medicine, namely to immunology, and can be applied for detection of contaminants in glucose polymers. For this purpose analysis of inflammatory response is carried out in vitro with application of cell line, which represents cell line of either macrophages or differentiable in macrophages, or cell, expressing one or several toll-like receptors (TLR) or NOD-like receptors, selected from TLR2, TLR4 and NOD2. Analysis contains the following stages: (a) placing macrophages in presence of preparation of glucose polymers, which can contain anti-inflammatory contaminants, and measuring cytokine RANTES production, with production of RANTES cytokine indicating to the fact that preparation contains contaminants capable of initiating inflammatory reaction, and (b) placing cell line, which makes it possible to detect activity of innate immunity receptor or several receptors of innate immunity, selected from TLR2 and NOD2, in presence of preparation and detection of signal of reporter gene, bound to said receptor, with detection of said activity or said signal indicates presence in preparation of contaminant, which represents receptor agonist.
EFFECT: application of claimed method makes it possible to detect contaminants of glucose polymers, and addition of components, such as MDP or LPS, in tested sample makes it possible to act synergistically with contaminants, which increases sensitivity and reduces threshold of detection, with synergetic response being registered for RANTES.
28 cl, 5 ex, 23 dwg, 5 tbl
SUBSTANCE: peripheral leukocyte blood values before and after a loading test are measured with the use of the gradual submaximal exercise. The method involves the differentiated recovery of different types of leukocytes from the blood to produce a preparation; a total T-cell (Tt) and active T-cell (Ta) count is determined; a Tt/Ta ratio is derived; mononuclear cells are incubated with granulocytes; a granulocyte-binding lymphocyte index (GLI) is determined in accordance with a granulocyte rosette formation (GRL - contact bound to three granulocytes) to granulocyte contact lymphocytes (GCL - contact bound to one granulocyte) ratio in the preparation; leukocyte indices: lymphocyte index (LI), immune reactivity index (IRI), adaptation index, ("CПHP") are determined; immune functional state adaptation coefficients (K) are derived for each value. Total immune functional body state TIFBS is calculated by formula TIFBS = K"спнр"+Kli+Kiri+Kgli+K"итл" before the exercise - TIFBS1 and after the exercise - TIFBS2. A specific immune functional state coefficient SIFSC is calculated by formula SIFSC = (TIFBS1+TIFBS2)/5, and a level of the immune functional SIFSC reserve is determined. If the SIFSC values are above +1.0, the level of the immune functional reserve is considered to be optimal; the SIFSC values falling within the range of 0 to 1.0 show the satisfactory reserve, whereas the SIFSC values below 0 shows the unsatisfactory reserve.
EFFECT: method enables assessing the functional body reserves with the use of combined characteristics including the adaptation body potential, immune reactivity and immune cell interaction.
SUBSTANCE: DNA is recovered from peripheral venous blood. Genetic polymorphisms of tumour necrosis factor α (-308 G/A TNFα), tumour necrosis factor 1 receptor (+36 A/G TNFR1), interferon-inducible T-cell chemoattractant (A/G I-TAC), interleukin 1A (-889 C/T IL-1A), lymphotoxin α (+250 A/G Ltα) are typed by polymerase chain reaction. A high risk of developing hyperplastic processes of endometrium is predicted if detecting a combination of alleles -308 G TNFα, +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles -308 G TNFα,+250 G Ltα, -889 T IL-1A.
EFFECT: higher accuracy.
2 dwg, 1 tbl, 1 ex
SUBSTANCE: chronic infectious-inflammatory diseases (CIIDs) are diagnosed. Clinical blood analysis and bacteriological tests are conducted. A sensibilisation index (SI) and an immune responsiveness index (IRI) are calculated; total microbial count per 1 m3 of the working space air is measured, and the total microbial number (TMN) is derived. If the TMN is less than 500 CFU/m3 with no CIIDs diagnosed accompanied by the SI of less than 1.08 standard units and the IRI of less than 13 standard units, the immunoassay is considered to be inadvisable. If the TMN falls within the range of 500-2,500 CFU/m3 with one CIID diagnosed accompanied by the SI from 1.08 to 1.3 standard units and the IRI from 13.1 to 15.7 standard units, the immunoassay with the first-level tests seems advisable. Whereas the TMN exceeding 2,500 CFU/m3 with at least two CIIDs accompanied by the SI of 1.4-1.5 standard units and the IRI of 15.8-18.3 standard units, the immunoassay with the second-level tests is thought expedient.
EFFECT: invention enables detecting the workers in need of further examination for the purpose of timely immune correction in the setting of mass routine examinations.
1 tbl, 3 ex
SUBSTANCE: DNA from peripheral venous blood is extracted. An analysis of a combination of genetic versions of polymorphous markers of genes of cytokines of the gene regulator of the activity of normal expression and secretion of T-cells (-403 G/A RANTES), macrophage protein -1β (+1931 A/T MIP 1β), factor of stromal cells (-801 G/A SDF1), interleukin -1 (-511 C/T IL-1B), monocyte chemoattractant protein -1 (C/G MCP-1), interleukin -4 (-590 C/T IL-4) is performed. An increased risk of development of a combination of uterine myoma with endometriosis and hyperplastic processes of the endometrium is predicted if the combination of alleles 403 A RANTES, G MCP-1,+1931 A MIP 1β, -590 C IL-4 or the combination of alleles -403 A RANTES,+1931 A MIP 1β, -801 G SDF1, -511 C IL-1B is identified.
EFFECT: application of the claimed method makes it possible to detect a group of patients with a risk of developing a combination of proliferative reproductive system diseases, which makes it possible to prescribe an adequate therapy to prevent further progressing of the diseases.
3 dwg, 2 ex
SUBSTANCE: invention deals with method of predicting level of arterial pressure in women of Russian nationality, born in Central Black Earth region of Russia. Method includes separation of DNA from lymphocytes of peripheral venous blood and analysis of genetic polymorphisms. +46G/A ADRB2 and 4a/4b eNOS by method of polymerase chain reaction Level of systolic arterial pressure in women in late pregnancy is predicted by results of multiple regression equation of the following type: Y1=15,455+2,544x1+9,946x2+0,736x3+4,716x4+0,185x5, where x1 is genetic variant in locus - 4a/4b eNOS, namely 4b4b=1; 4a4b=2; 4a4a=3; x2 is presence of preeclampsia in relatives: yes=0, no=1; x3 is level of systolic arterial pressure before pregnancy, mm Hg; x4 is presence of cardiovascular system pathology: yes=0, no=1; x5 is woman's weight before pregnancy, kg Level of diastolic arterial pressure in women in late pregnancy is predicted, for which purpose multiple regression equation of the following type is used: Y2=14,200+7,768x1-2,877x2+7,500x3+0,414x4+3,668x5, where x1 is genetic variant in locus - 4a4b eNOS, namely 4b4b+4a4b=1, 4a4a=0; x2 is genetic variant in locus +46G/A ADRB2, namely GG+GA=1, AA=0; x3 is presence of preeclapsia in relatives:yes=0, no=1; x4 is systolic arterial pressure before pregnancy, mm Hg; x5 is presence of cardiovascular system pathology: yes=0, no=1.
EFFECT: invention makes it possible to realise early prediction of increase of arterial pressure level in women in late pregnancy, will make it possible to form of women at the stage of pregravidal preparation and at early terms of pregnancy groups of high risk of developing hypertension in late pregnancy, as well as realise required therapeutic-preventive measures aimed at prevention of development of said pregnancy complication in due time.
2 dwg, 2 tbl, 1 ex
SUBSTANCE: method is based on contacting a membrane test strip with an analysed fluid sample and initiating thereby a motion along the test strip membranes of reagents being parts of the sample or coating the membrane, and forming the immune complexes to be detected in the course of reactions in the membrane pores or on the surface thereof. A distinguishing feature of the presented method for antigen detection is that the test strip is coated additionally within the test sample contact area with a certain amount of specific antibodies, which react to the detected antigen expected to be found in the sample, when a fluid front moves and block a certain number of binding sites. The number of the coating free antibodies is specified so that the low content thereof in the analysed sample being of no diagnostic importance ensures blocking the binding sites completely that prevents the antigen from binding in the analysed area of the test strip and from developing a destructive staining in the analysed area.
EFFECT: presented approach enables reliable diagnosing based on the detection results of the antigens of gastrointestinal disorders, avoiding the achievement of positive test results for the low-antigen samples, which testifies to no development of the disease in an individual.
1 tbl, 2 ex
SUBSTANCE: invention relates to biochemistry. Described are antibodies and fragments thereof, having high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers. Disclosed are compositions which contain the described antibody or a fragment thereof, methods of detecting α-synuclein protofibrils using the described antibody or fragment thereof. In other versions, the present invention relates to methods of preventing, slowing down the development or treating a neurodegenerative disorder with α-synuclein pathology, where said methods include administering the described antibody or fragment thereof. The invention also relates to use of said antibody or fragment thereof to obtain a pharmaceutical composition for treating a neurodegenerative disorder with α-synuclein pathology.
EFFECT: invention is used for diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods of reducing or inhibiting α-synuclein aggregation by administering said antibody or fragment thereof.
31 cl, 9 dwg, 4 tbl, 10 ex
SUBSTANCE: method comprises immunoaffinity chromatography using mini-antibodies a-hLF-1 and a-hLF-4, which amino acid sequences are presented as SEQ ID NO:1 and SEQ ID NO:2. The invention may be used to obtain highly purified fraction of human lactoferrin.
EFFECT: invention enables to carry out with high efficiency the separation of proteins of lactoferrin of human and goat consisting in milk, using the single-domain mini-antibodies.
6 dwg, 2 ex
SUBSTANCE: invention refers to biotechnology and immunology. The method provides administering an antibody which binds to an advanced glycation end product. What is also described is using this antibody for producing a therapeutic agent. The invention can be used in medicine.
EFFECT: disclosed is a method for promoting the regenerative processes in a tissue culture or a cell culture.
12 cl, 1 dwg, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and immunology. What is presented is a hybridoma cell line FP12H3-C2 deposited under No. DSM ACC2750 producing the anti-beta-amyloid antibody. Presented are methods for preparing an antibody, including a humanised antibody with using a hybridoma line according to the invention, as well as diagnostic techniques for a beta-amyloid associated disease or condition in a patient or a liability to such disease or condition, a method for determining a degree of the tissue involvement into amyloidogenic plaques, a method for monitoring minimal residual signs of the disease into a patient following treating with the antibody or its active fragment, a method for prediction of sensitivity in the patient treated with the antibody or its active fragment.
EFFECT: present invention can find further application in diagnosing and therapy of beta-amyloid related diseases, such as Alzheimer disease.
9 cl, 4 dwg, 5 tbl, 17 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and represents anti-nerve growth factor (NGF) antibodies. The present invention also discloses a pharmaceutical composition for relieving pain associated with a disease or a condition, wherein pain progression or persistence is mediated by NGF, containing the above antibodies, as well as a kit for treating a HGF-related disease, such as e.g. osteoarthritis, nucleic acids coding a heavy or light chain of the antibody, an expression vector, a host cell for preparing the above antibodies, a method for expressing the above anti-NGF antibodies, as well as using the above antibodies in managing pain and for preparing a therapeutic agent for managing pain associated with the disease or condition, wherein pain progression or persistence is mediated by NGF.
EFFECT: present invention enables producing the anti-NGF antibodies characterised by high stability in vivo.
16 cl, 7 dwg, 13 tbl, 8 ex
SUBSTANCE: invention refers to immunology. Presented are anti-Dickkopf 1 (anti-Dkk-1) antibodies and their functional fragments specified among the antibodies: 1) containing CDR1 VH containing the amino acid sequence SSYAIS, SYAIS or GFTFSSY; CDR2 VH containing the amino acid sequence SVSGTGLGFGTYYPDSVKG or SVSGTGLGFGTY; and CDR3 VH, containing the amino acid sequence TSLENYAFDY or SLENYAFDY; and CDR1 VL containing the amino acid sequence RASESVDDFGISFIN; CDR2 VL containing the amino acid sequence AGSKQGS; and CDR3 VL containing the amino acid sequence QQLKEVPPT; and 2) the antibodies disclosed in Table 4 presented in the application materials. Described are: nucleic acids coding the above antibodies or their functional fragments; expression vectors containing the above nucleic acids; and cells used for expression of the above antibodies or their functional fragments and containing the above expression vectors. Presented is a method for producing the antibody or its functional fragment involving the stage of culturing the above expression cell. Disclosed is a composition possessing Dkk-1 binding activity, containing the antibody or its functional fragment in a therapeutically effective amount and a pharmaceutically acceptable excipient, thinner or carrier.
EFFECT: invention enables extending the range of products for treating the diseases associated with Dkk-1 and LRP5/6 excessive reaction, which cause Wnt activation.
14 cl, 14 dwg, 14 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. There are described pharmaceutical compositions for treating ophthalmic diseases associated with pathological abnormalities/changes of visual tissues, especially associated with amyloid-beta related pathological abnormalities/changes of the visual tissues, containing antibodies specifically recognising and binding specific epitopes from the range of β-amyloid proteins. There are also presented methods for reducing the load/plaque count in the retinal gangliocyte layer in a mammal suffering from an analogous ophthalmic disease. Besides, there are presented a method for reducing the total amount of soluble amyloid-β in the mammalian retinal gangliocyte layer, a method for preventing manifestations of the analogous ophthalmic disease, a method of treating or relieving the manifestations of the analogous ophthalmic disease. A method for maintaining or reducing an ocular tension in an animal suffering from the analogous ophthalmic disease. All the methods involve administering the described composition.
EFFECT: invention extends the methods and compositions for diagnosing and treating the amyloid diseases that represent a group of amyloid protein related diseases and disorders, eg Alzheimer disease.
55 cl, 20 dwg, 7 tbl, 18 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. What is described is a pharmaceutical composition used for treating and/or preventing pathological bone metabolism and containing this antibody. The invention can be used in medicine.
EFFECT: antibody and its functional fragment specifically recognising human Siglec-15 and possessing the osteoclast inhibitory activity are described.
73 cl, 57 dwg, 4 tbl, 33 ex
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and can be used for treating ocular diseases associated with amyloid-beta related pathological abnormalities/changes in the visual system tissues. That is ensured by administering a pharmaceutical composition, which contains a therapeutically effective amount of a humanised antibody or antigen-binding fragment, wherein the humanised antibody or its fragment is able to bind amyloid-beta. Presented are preventing, treating or relieving symptoms of an ocular disease, reducing the plaque load of retinal ganglion cells, diagnosing the ocular disease and diagnosing a predisposition to the ocular disease, prolonging the patient's sensitivity when treating with the pharmaceutical composition for treating the ocular disease.
EFFECT: group of inventions provides the effective treating of the above ocular pathology by using the composition containing the high-specific antibodies, which specifically recognise and bind to specific epitopes of various β-amyloid proteins.
20 cl, 18 dwg, 9 tbl, 18 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry. What is described is an anti-Tau phospho Serine 422 (pS422) antibody for treating taupathy, characterised by the fact that it specifically binds to a phosphorylated Tau fragment of the sequence SEQ ID NO:9 and to Tau pS422, and binds to other than Tau and phosphorylated MSAC fragment of the sequence SEQ ID NO:17. What is presented is the pharmaceutical composition for treating taupathy, as well as a method of treating taupathy. What is presented is a method for preparing the above antibody.
EFFECT: invention extends the range of products for treating taupathy.
21 cl, 11 dwg, 7 tbl, 12 ex
SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.
EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.
27 cl, 8 dwg, 21 tbl, 11 ex